What is FDA &
Why It Exists
A complete, expert-level guide to the U.S. Food and Drug Administration — its constitutional authority, historical origins, organizational structure, jurisdiction, enforcement philosophy, and what every global exporter must understand before a single shipment crosses the U.S. border.
What the FDA Actually Is
The Food and Drug Administration (FDA) is a federal regulatory agency of the United States government, operating within the Department of Health and Human Services (HHS). It is one of the oldest and most powerful consumer protection agencies in the world, with authority over products that account for roughly twenty cents of every dollar spent by American consumers.
FDA's jurisdiction spans an extraordinary range of products: human food and animal feed, prescription drugs, over-the-counter medications, medical devices, cosmetics, dietary supplements, biological products (including vaccines and blood supply), and products that emit radiation. In 2024, FDA regulated over $2.8 trillion worth of products annually — more than the GDP of most countries.
But here is what most people outside the United States misunderstand: FDA is not a testing agency. It does not test every drug, every food shipment, or every device before it enters the market. Instead, FDA sets the legal standards, reviews submissions and applications, conducts inspections, monitors post-market safety, and enforces compliance. The burden of proving safety and effectiveness rests entirely with the manufacturer — not with FDA. This distinction is foundational to understanding why regulatory consultants exist and why their work matters.
The Burden Is Always on the Company
Under U.S. law, a product is presumed non-compliant until the manufacturer demonstrates otherwise. FDA doesn't have to prove your product is unsafe — you have to prove it's safe, effective, and properly labeled. This shifts an enormous compliance burden onto companies and creates the professional space that regulatory consultants occupy.
Why FDA Exists — The History That Explains Everything
FDA was not created out of bureaucratic ambition. Every significant expansion of FDA's authority can be traced directly to a public health disaster — a tragedy so severe that Congress had no choice but to act. Understanding this history explains why FDA takes compliance so seriously, and why the consequences of non-compliance are so severe.
The 1937 Elixir Sulfanilamide Disaster
In 1937, a Tennessee pharmaceutical company formulated sulfanilamide — a drug effective against streptococcal infections — using diethylene glycol as a solvent. Diethylene glycol is toxic. No safety testing was done. Over 107 people died, mostly children. The company had violated no law, because at the time, no law required drug safety testing before sale.
Congress responded with the Federal Food, Drug, and Cosmetic Act of 1938 — the foundational statute that gave FDA its modern authority and required drugs to be proven safe before marketing. This single disaster created the regulatory framework that governs your clients' products today.
The 1961 Thalidomide Near-Miss
In Europe, thalidomide was widely prescribed as a sedative and treatment for morning sickness in pregnant women. It caused severe birth defects — shortened or absent limbs — in thousands of children. In the United States, FDA medical officer Dr. Frances Kelsey refused to approve thalidomide despite significant pressure from the manufacturer, citing insufficient safety data. The U.S. was largely spared. Congress then passed the Kefauver-Harris Drug Amendments of 1962, requiring drugs to be proven effective as well as safe — creating the modern clinical trial system.
Why This History Matters for Consultants
Every time you explain to a client why FDA requires a particular form, a particular test, or a particular label element — the answer traces back to a specific historical failure. FDA is not arbitrary. When FDA requires drug manufacturers to submit bioequivalence data, it's because patients died from drugs that didn't work as expected. When FDA requires allergen labeling, it's because people died from undisclosed ingredients. Knowing the "why" behind regulations makes you a dramatically more persuasive consultant.
FDA's Legal Authority — Where the Power Comes From
FDA derives its authority primarily from Title 21 of the United States Code (21 U.S.C.), which codifies the Federal Food, Drug, and Cosmetic Act and related statutes. The specific legal authority that FDA uses most frequently is found in 21 U.S.C. §§ 301–399d.
FDA's power is not unlimited — it is constrained by what Congress has authorized. However, within its authorized domain, FDA has remarkably broad authority: it can prohibit importation of products, seize goods already on the market, compel recalls (under certain statutes), and refer cases to the Department of Justice for criminal prosecution.
The Two Core Legal Concepts That Define Violations
Both violations are strict liability offenses for misdemeanor charges. This means that under 21 U.S.C. § 333(a)(1), a company officer can be criminally convicted for selling adulterated or misbranded products even if they had no knowledge of the violation and took no deliberate action. This is called the "responsible corporate officer doctrine" — established in United States v. Park (1975). It is a powerful reason why compliance is not optional.
What FDA Regulates — And What It Doesn't
One of the most practical skills for any FDA consultant is knowing precisely where FDA's jurisdiction begins and ends, and where it overlaps with other agencies. Clients often assume FDA regulates everything health-related — or conversely, that their product doesn't need FDA involvement. Both assumptions are often wrong.
| Product/Area | Regulating Agency | Key Practical Point |
|---|---|---|
| Human food & beverages | FDA (CFSAN) | Includes bottled water, dietary supplements, food additives, food contact materials |
| Meat, poultry, processed eggs | USDA / FSIS | NOT FDA — common confusion; requires USDA mark of inspection |
| Alcohol beverages | TTB (Treasury) + FDA for labeling | FDA regulates added ingredients; TTB regulates alcohol content and advertising |
| Prescription drugs | FDA (CDER) | Requires approved NDA/ANDA before U.S. marketing |
| OTC drugs | FDA (CDER) | Must conform to OTC monograph or have NDA approval |
| Medical devices | FDA (CDRH) | Classification determines pathway — Class I/II/III |
| Cosmetics | FDA (CFSAN) | Now mandatory registration under MoCRA (2022) |
| Dietary supplements | FDA (CFSAN) | No pre-market approval, but strict GMP and claims rules |
| Biological products (vaccines, blood) | FDA (CBER) | Requires Biologics License Application (BLA) |
| Animal food and feed | FDA (CVM) + USDA | Pet food is FDA; meat in pet food may involve USDA |
| Veterinary drugs | FDA (CVM) | Requires NADA or ANADA — separate from human drug pathways |
| Pesticides | EPA (primarily) + FDA | EPA sets tolerances; FDA enforces them in food |
| Drug advertising (DTC) | FDA (OPDP) + FTC | FDA regulates prescription drug advertising; FTC regulates OTC and supplement ads |
| Controlled substances | DEA + FDA | DEA schedules; FDA approves the drug application |
The Herbal Tea from Sri Lanka
A Sri Lankan exporter produces a popular herbal tea. They want to export to the U.S. They assume that because it's "just tea," it requires minimal regulatory steps. They're partially right — but here's what they actually need:
- FDA food facility registration (because they manufacture food for U.S. consumption)
- A U.S. Agent designated in their FDA registration
- Prior Notice filed before every shipment
- A U.S.-compliant label with Nutrition Facts, ingredient list, allergen declaration, and net quantity in U.S. and metric units
- GRAS verification that all herbal ingredients are permitted under U.S. law
- If any marketing claim suggests the tea "supports immune health" → structure/function claim requirements apply
- If any marketing claim says the tea "treats colds" → it just became an unapproved drug
The Most Important Distinction — Registration vs. Approval
This single misunderstanding causes more client compliance failures than almost anything else. Let's be absolutely precise:
Illegal claim: "FDA Approved" — If a food company, dietary supplement company, or cosmetic company labels their product "FDA Approved," they have committed misbranding under 21 U.S.C. § 343(a). FDA has never approved their product. The claim is false. FDA actively sends warning letters for exactly this violation — and it's one of the first things an import examiner looks for. If you see this on a client's label, it must be removed before the product enters the U.S.
What Clients Can Legally Say
| Product Type | Legal Claim | Illegal Claim |
|---|---|---|
| Food / Cosmetic | "Manufactured in an FDA-registered facility" | "FDA Approved" / "FDA Certified" |
| Medical Device (510k) | "FDA Cleared" / "510(k) Cleared" | "FDA Approved" (unless PMA) |
| Medical Device (PMA) | "FDA Approved" | Any claim beyond approved indications |
| Prescription Drug | "FDA Approved" (if NDA/ANDA approved) | Claims beyond approved labeling |
| Dietary Supplement | "Made in an FDA-registered, GMP-compliant facility" | "FDA Approved" / disease claims |
FDA's Enforcement Philosophy
Understanding how FDA thinks about enforcement is as important as knowing the regulations themselves. FDA does not pursue every violation equally. It operates under a risk-based philosophy — focusing the most intensive scrutiny on products and situations that pose the greatest threat to public health.
The Risk-Based Prioritization Framework
FDA allocates its inspection and enforcement resources based on risk. This means:
- Infant formula facilities are inspected more frequently than candy manufacturers
- Injectable drugs face more intensive cGMP scrutiny than topical OTC products
- Class III medical devices (life-sustaining implants) require full clinical approval, while most Class I devices need only basic registration
- High-risk countries for specific product categories receive elevated screening rates at U.S. ports of entry
This risk-based approach does not mean low-risk categories are unregulated. It means FDA focuses its finite resources proportionally — but any regulated product can be inspected, detained, or recalled at any time.
"FDA's job is not to make it easy to sell products in the United States. FDA's job is to make it safe. Those goals sometimes conflict — and when they do, safety wins."
— Standard framing used in FDA regulatory affairs training programsStrict Liability — Why Intent Doesn't Matter for Misdemeanors
Under 21 U.S.C. § 333(a)(1), selling adulterated or misbranded products is a misdemeanor — regardless of intent. A company that unknowingly ships food containing an undeclared allergen can still face criminal misdemeanor charges against its officers. Under the responsible corporate officer doctrine (established in United States v. Dotterweich, 1943, and reaffirmed in United States v. Park, 1975), senior executives can be personally convicted even if they had no personal knowledge of the violation.
This is not a theoretical threat. FDA has pursued criminal charges against corporate officers in cases involving contaminated food, falsified drug testing records, and medical device quality system failures. For your clients, this is why compliance isn't just a regulatory formality — it is personal legal protection for the people running the company.
How FDA is Funded — User Fees and What They Mean
FDA receives funding from two sources: congressional appropriations (taxpayer money) and industry user fees. User fees are paid by companies when they submit applications or register facilities in certain product categories. Understanding user fees is essential for advising clients on budget.
| Fee Program | What It Covers | FY2025 Key Fee |
|---|---|---|
| PDUFA — Prescription Drug User Fee Act | Funds NDA/BLA review for branded prescription drugs | NDA Application Fee: ~$4.05M |
| GDUFA — Generic Drug User Fee Act | Funds ANDA review for generic drugs; foreign facility fees | Foreign Facility Fee: ~$75,000/year |
| MDUFA — Medical Device User Fee Act | Funds 510(k), PMA, De Novo review timelines | 510(k) Standard: ~$21,000; PMA: ~$450,000 |
| BSUFA — Biosimilar User Fee Act | Funds biosimilar BLA review | Application Fee: ~$3.4M |
| Food Facility Registration | No fee — registration is free | $0 |
| Device Establishment Registration | Annual registration for device facilities | Foreign Establishment: ~$6,800/year |
| MoCRA (Cosmetics) | Cosmetic facility registration | Currently $0 (subject to change) |
Small Business Waivers and Reductions: FDA offers reduced user fees for small businesses — typically companies with gross revenues under $100 million. Under PDUFA, a company's first human drug application may receive a full fee waiver if it has annual revenues below $50M. Always check current small business fee schedules at fda.gov/industry/prescription-drug-user-fee-amendments — fee levels are updated each fiscal year (October 1).
What Happens When a Product Doesn't Comply
For international exporters, the most immediate consequence of FDA non-compliance is what happens at the U.S. border. FDA works with U.S. Customs and Border Protection (CBP) to screen all regulated product imports. The consequences escalate based on the nature and severity of the violation.
The Import Consequence Ladder
| Consequence | Trigger | Practical Impact |
|---|---|---|
| Released Without Examination | Product and facility have clean history; proper Prior Notice filed | Best outcome — product clears quickly |
| Document Review | FDA wants to review labels, Prior Notice, or manifests before release | Delay of hours to days |
| Physical Examination | Risk-based selection or prior compliance issues | Shipment held; FDA field officer inspects and may sample |
| Notice of Detention | FDA has reason to believe product is in violation | Shipment held; importer has ~30 days to respond with evidence of compliance or request hearing |
| Refusal of Admission | Product is determined to be in violation; detention period expired without resolution | Product must be exported out of the U.S. or destroyed. Storage costs are the importer's burden. |
| Import Alert | Pattern of violations; serious GMP failures; fraudulent submissions | ALL future shipments from the facility are automatically detained without physical examination. Can last years. |
The Seafood Exporter with No Prior Notice
A Vietnamese seafood processor has been exporting frozen fish to U.S. restaurants for three years. Their U.S. buyer starts handling their own logistics and forgets to file Prior Notice for a particular shipment — a $180,000 container of frozen tuna.
When the vessel arrives at the Port of Los Angeles, CBP flags the entry: no Prior Notice on file for this shipment. FDA issues an immediate refusal. The container cannot enter the U.S. The importer has two options: re-export the entire container back to Vietnam (ocean freight cost: ~$12,000) or destroy it under U.S. Customs supervision (destruction cost: ~$8,000 plus the full $180,000 product loss).
The Vietnamese exporter had done nothing wrong. Their facility was registered. Their products were safe. A single procedural omission — no Prior Notice — cost approximately $200,000.
FDA's Five Centers — A Practical Map
FDA is organized into product-specific centers, each responsible for a category of regulated goods. As a consultant, you'll spend most of your time dealing with CFSAN and CVM for food and veterinary products, CDER for drugs, CDRH for devices, and CFSAN again for cosmetics. CBER (biologics) is typically the domain of highly specialized firms.
Key programs: Food Facility Registration, FSMA implementation, MoCRA (cosmetics), GRAS determinations, food labeling regulations.
CFR: 21 CFR Parts 1–199
Key programs: NDA (New Drug Application), ANDA (generic drugs), Drug Listing via SPL, cGMP inspections, drug advertising review through OPDP.
CFR: 21 CFR Parts 200–499
Key programs: 510(k) clearance, PMA approval, De Novo classification, UDI system, GUDID database, Device Quality System (21 CFR Part 820).
CFR: 21 CFR Parts 800–898
Key programs: NADA (New Animal Drug Application), ANADA (generic animal drug), animal food facility registration, veterinary drug GMP.
CFR: 21 CFR Parts 500–599
Key programs: BLA (Biologics License Application), IND for biologics, lot release testing for vaccines and blood products, biosimilar applications (351(k) pathway).
Note for consultants: CBER work is highly specialized. Unless your firm has specific biologics expertise, the right move is to refer CBER-regulated clients to a biologics-specialized consultancy. Knowing the boundary of your competence is as important as the competence itself.
CFR: 21 CFR Parts 600–680
What This Means for You as a Regulatory Consultant
Every concept in this module has a direct consulting application. Here is how the foundational understanding of FDA translates into professional practice:
The CFR — Your Primary Reference Document
The Code of Federal Regulations (CFR) is where FDA's rules actually live. Congress passes laws (statutes), and FDA implements those laws through regulations published in the CFR. When you cite "FDA regulations," you're citing the CFR. When FDA cites violations in a Warning Letter, it cites the CFR. Every regulatory deliverable you produce for a client should reference specific CFR provisions.
How to Access the CFR: The official, always-current version of the CFR is at ecfr.gov (Electronic Code of Federal Regulations). It is free, searchable, and updated in real time as rules change. This is the only source you should use when advising clients — never rely on secondary summaries for the text of a regulation.
- FDA is a federal regulatory agency, not a testing agency. The burden of proving safety and compliance rests entirely on the manufacturer.
- FDA's authority derives from Title 21 of the U.S. Code, implementing the FD&C Act and related statutes. Every major expansion of FDA's power followed a public health disaster.
- The two foundational legal concepts are adulteration (unsafe or impure product) and misbranding (false or incomplete labeling). Both are strict liability offenses at the misdemeanor level.
- Registration, Clearance, and Approval are legally distinct terms. Calling a food or cosmetic "FDA Approved" is illegal misbranding — the most common mistake international brands make.
- FDA operates five major product centers: CFSAN (food/cosmetics), CDER (human drugs), CDRH (devices), CVM (veterinary), and CBER (biologics). Knowing which center governs a product defines the entire regulatory pathway.
- For international exporters, the most immediate consequence of non-compliance is border detention or refusal — products can be refused entry, re-exported, or destroyed at full cost to the importer.
- All FDA regulations are codified in Title 21 of the CFR. Competent consultants cite specific CFR provisions in every professional deliverable — ecfr.gov is the authoritative source.